Ontology highlight
ABSTRACT: Purpose
We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive.Experimental design
The seven most common KRAS mutations in codon 12 and codon 13 were examined in 2,478 BRAF-wild-type tumors. Because KRAS mutations in codon 12 (n = 779) or 13 (n = 220) were not predictive of adjuvant cetuximab benefit, study arms were pooled for analysis. Disease-free survival (DFS) was evaluated by HRs using Cox models.Results
KRAS mutations in codon 12 (multivariate HR, 1.52; 95% confi
SUBMITTER: Yoon HH
PROVIDER: S-EPMC4040326 | biostudies-literature | 2014 Jun
REPOSITORIES: biostudies-literature